Top Market Shifts Transforming the Colorectal Cancer Molecular Diagnostics Market Landscape: Key Insights

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

What Is the Expected CAGR for the Colorectal Cancer Molecular Diagnostics Market Through 2025?
The market size for molecular diagnostics of colorectal cancer has significantly expanded in the past few years. The market is anticipated to rise from $2.56 billion in 2024 to $2.77 billion in 2025, exhibiting a compound annual growth rate (CAGR) of 8.1%. Factors responsible for this growth during the historic period include a heightened prevalence of colorectal cancer, elevated consciousness and screening initiatives, an increased focus on tailored medicine, and governmental cancer control initiatives.

What's the Projected Size of the Global Colorectal Cancer Molecular Diagnostics Market by 2029?
In the coming years, the market size of colorectal cancer molecular diagnostics is predicted to surge significantly. It is projected to reach $3.79 billion by 2029, growing at a compound annual growth rate (CAGR) of 8.1%. Factors contributing to this projected growth during the forecast period include an aging populace with enhanced risk factors, the integration of genomic data into clinical practices, increased usage of precision medicine approaches, and worldwide collaborations in cancer research. The forecast period will also see major trends such as a greater focus on early detection biomarkers, the use of artificial intelligence (AI) in data interpretation, a rise in circulating tumor DNA (CTDNA) analysis, further development of companion diagnostics for targeted treatments, and increased attention towards immunotherapy biomarkers.

View the full report here:
https://www.thebusinessresearchcompany.com/report/colorectal-cancer-molecular-diagnostics-global-market-report

Top Growth Drivers in the Colorectal Cancer Molecular Diagnostics Industry: What's Accelerating the Market?
The rise of inflammatory bowel diseases (IBD), which are long-term gastrointestinal disorders characterized by inflammation of the digestive tract, primarily the colon and rectum*, is anticipated to fuel the expansion of the colorectal cancer molecular diagnostic market. Common symptoms like abdominal discomfort, diarrhea, and weight loss are managed through medication, lifestyle alterations, and occasionally surgery. The growing prevalence of IBD enhances the necessity for precise, effective, and progressive diagnostic tools. These diagnostics are crucial as the choice of systemic therapy for colorectal cancer (CRC) primarily depends on the molecular evaluation of the tumor. For example, according to UK Parliament-backed research by Crohn's & Colitis UK in April 2024, half a million people in the UK were living with IBD, almost twice the earlier estimates. Consequently, the upsurge in inflammatory bowel diseases (IBD) incidences is anticipated to stimulate the colorectal cancer molecular diagnostic market's growth. The growth of the colorectal cancer molecular diagnostics market is further driven by the increasing prevalence of colorectal cancer. Colorectal cancer is a dangerous disease affecting the colon or rectum*, parts of the digestive system. This cancer manifests when cells in the colon or rectum* uncontrollably grow and form a tumor. The rise in colorectal cancer rates intensifies the need for molecular diagnostics for detecting and treating cancer. As an instance, data from the American Cancer Society in March 2023 projects that around 153,020 individuals will be diagnosed with CRC (colorectal cancer) with an expected death toll of approximately 52,550. Moreover, of these figures, there would be 19,550 cases and 3,750 deaths occurring in individuals below 50 years old. Hence, the increasing incidence of colorectal cancer continues to ramp up the expansion of the colorectal cancer molecular diagnostics market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=13120&type=smp

What Trends Will Shape the Colorectal Cancer Molecular Diagnostics Market Through 2029 and Beyond?
Leading companies in the colorectal cancer molecular diagnostic market are focused on creating cutting-edge molecular diagnostics and personalized medicine solutions like the shield blood test approach for early detection of colorectal cancer, making it more manageable. The shield blood test is a preliminary test developed to detect early-stage colorectal cancer (CRC). For instance, in May 2022, Guardant Health, a biotechnology firm offering molecular diagnostic products for oncology in the US, introduced its Shield Blood Test. This easy-to-administer test addresses the issue of patient receptiveness to regular screening, requiring only a straightforward blood draw. It demonstrated a 91% sensitivity in detecting colorectal cancer and a 20% sensitivity for detecting advanced adenomas, with a specificity of 92%. The Shield test identifies early colorectal cancer signals in the blood, using data from over 2,000 colorectal cancer subjects, 357 advanced adenoma subjects, and 3,757 healthy subjects.

What Are the Main Segments in the Colorectal Cancer Molecular Diagnostics Market?
The colorectal cancer molecular diagnostics market covered in this report is segmented -

1) By Type: Instruments, Reagents And Kits, Services
2) By Technology: Polymerase Chain Reaction (PCR), Sequencing, Mass Spectrometry, Transcription Mediated Amplification, Chips And Microarrays, Isothermal Nucleic Acid Amplification Technology (INAAT)
3) By End Users: Hospitals, Ambulatory Surgical Centers, Diagnostic Laboratories, Homecare Settings

Subsegments:
1) By Instruments: PCR Machines, Sequencers, Microarrays
2) By Reagents And Kits: DNA Or RNA Extraction Kits, Assay Kits, Reagent Packs
3) By Services: Diagnostic Testing Services, Genetic Testing Services, Consultation Services

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=13120&type=smp

Which Top Companies are Driving Growth in the Colorectal Cancer Molecular Diagnostics Market?
Major companies operating in the colorectal cancer molecular diagnostics market report are Johnson & Johnson, Bayer AG, Abbott Laboratories, Danaher Corporation, Becton Dickinson and Company, Biocartis Group NV, Agilent Technologies Inc., Grifols S.A, Hologic Inc., Biomérieux SA, Quidel Corporation, Bio-Rad Laboratories Inc., Qiagen N.V., Exact Sciences Corporation, Illumina Inc., Cepheid, Myriad Genetics Inc., Guardant Health, Luminex Corporation, GenMark Diagnostics, Amoy Diagnostics Co. Ltd., MDxHealth Inc., HTG Molecular Diagnostics Inc., GenPath Diagnostics, geneOmbio Technologies Pvt.

Which Regions Will Dominate the Colorectal Cancer Molecular Diagnostics Market Through 2029?
North America was the largest region in the colorectal cancer molecular diagnostics market in 2024. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the colorectal cancer molecular diagnostics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13120

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 7882 955267,
Asia: +91 88972 63534,
Americas: +1 310-496-7795 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.